Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 1

A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

NCT07053384 · View on ClinicalTrials.gov ↗

Study Summary

This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen (Population 2).

Conditions Studied

Interventions

  • BIOLOGICAL VH3810109
  • DRUG Fostemsavir (FTR)
  • DRUG SOC INSTI-based ART

Study Locations (20)

Other

  • GSK Investigational Site — Brussels
  • GSK Investigational Site — Ghent
  • GSK Investigational Site — Aarhus
  • GSK Investigational Site — Hvidovre
  • GSK Investigational Site — Rotterdam
  • GSK Investigational Site — Barcelona
  • GSK Investigational Site — Barcelona

California

  • GSK Investigational Site — Bakersfield
  • GSK Investigational Site — San Diego

Florida

  • GSK Investigational Site — Ft. Pierce
  • GSK Investigational Site — Orlando

Missouri

  • GSK Investigational Site — Kansas City
  • GSK Investigational Site — St Louis

Pennsylvania

  • GSK Investigational Site — Philadelphia
  • GSK Investigational Site — Pittsburgh

Texas

  • GSK Investigational Site — Dallas
  • GSK Investigational Site — Dallas

Illinois

  • GSK Investigational Site — Chicago

New York

  • GSK Investigational Site — New York

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-07-10
Est. Completion 2028-03-24
Phase Phase 1

Sponsor

ViiV Healthcare

82 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07053384

The ClinicalTrials.gov registry entry for NCT07053384 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 82 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions — of which VH3810109 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07053384 reports 20 study locations spanning 9 distinct geographic areas — top geographies include Other, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07053384 about?

NCT07053384 is a clinical study titled "A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV". This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase str...

What is the current status of trial NCT07053384?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-07-10. Estimated completion is 2028-03-24.

What conditions does trial NCT07053384 study?

This clinical trial studies the following conditions: HIV Infections. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07053384?

The interventions under investigation include: VH3810109 (BIOLOGICAL), Fostemsavir (FTR) (DRUG), SOC INSTI-based ART (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07053384?

This trial is sponsored by ViiV Healthcare, which has 82 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07053384 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial